{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:46:55Z","timestamp":1768366015663,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007637","name":"German University in Cairo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007637","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The complement system is an essential part of the innate immunity that is involved in the elimination of pathogens as well as participating in the body\u2019s immune surveillance against cancer. However, recent findings have shown that cancerous cells can use the complement components to assist in certain hallmarks which are fundamental for tumor progression. The current study investigates the differential expression of membrane-bound complement regulatory proteins; CD46 and CD55 in leukemia. Clinical peripheral blood samples of newly diagnosed acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients were used to assess the changes in transcriptional expression levels of both proteins using quantitative real time PCR. Results showed that both CD46 and CD55 were significantly downregulated by 2 to 7 folds in both AML and ALL patients compared to healthy controls which is suggestive of a defense mechanism conducted by leukemic cells to overcome immune defenses. Flow cytometric analysis conducted for proteomic expression of CD46 and CD55 on cell surfaces of leukemia patients showed a reduction in expression by 1.2-fold and 2.8-fold in AML patients, respectively. Post transcriptional knockdown of both genes in leukemic cell model using customized shRNA, followed by cell viability assays showed a significant reduction in the viability of cells by 3-fold, suggesting that although the expression of both proteins could be compromised by cancerous cells to evade complement attack mechanisms, they could also be vital to the viability of cancerous cells suggesting a dual role of complement in the tumor microenvironment.<\/jats:p>","DOI":"10.1038\/s41598-025-33359-y","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:14:04Z","timestamp":1768263244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia and acute myelogenous leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"Lobna A.","family":"Onsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perihan","family":"Ammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisham","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Abou-Aisha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"El-Azizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"33359_CR1","unstructured":"Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology. In Immunology. 7th ed. 3\u2013104 (Elsevier, 2006)."},{"key":"33359_CR2","doi-asserted-by":"crossref","unstructured":"Taylor, P. R. et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. 192(3), 359\u2013366 (2000).","DOI":"10.1084\/jem.192.3.359"},{"key":"33359_CR3","doi-asserted-by":"crossref","unstructured":"Hourcade, D., Holers, V. M. & Atkinson, J. P. The regulators of complement activation (RCA) gene cluster. Adv. Immunol. 45 (1989).","DOI":"10.1016\/S0065-2776(08)60697-5"},{"key":"33359_CR4","unstructured":"Harris, C. & Paul, M. B. In The Complement System Novel Roles in Health and Disease. The Many Faces of the Membrane Regulators of Complement. (eds Szebeni, J.) (Kluwer Academic, 2004)."},{"key":"33359_CR5","doi-asserted-by":"crossref","unstructured":"Mcnearney, T., Seya, T. & Atkinson, J. P. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. ;84(2), 538\u2013545 (1989).","DOI":"10.1172\/JCI114196"},{"key":"33359_CR6","doi-asserted-by":"crossref","unstructured":"Seya, B. Y. T., Turner, J. R. & Atkinson, J. P. Purification and characterization of a membrane protein(gp45-70) that is a cofactor for cleavage of C3b and C4b. ;163, 837\u2013855 (1986).","DOI":"10.1084\/jem.163.4.837"},{"key":"33359_CR7","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.4049\/jimmunol.168.12.6298","volume":"168","author":"ML Barilla-labarca","year":"2002","unstructured":"Barilla-labarca, M. L. et al. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J. Immunol. 168, 6298\u20136304. https:\/\/doi.org\/10.4049\/jimmunol.168.12.6298 (2002).","journal-title":"J. Immunol."},{"key":"33359_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nature01315","volume":"421","author":"C Kemper","year":"2003","unstructured":"Kemper, C. et al. CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421, 1\u20135 (2003).","journal-title":"Nature"},{"key":"33359_CR9","unstructured":"Nicholson-Weller, A. & Wang, C. Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med 123(4), 485\u2013491."},{"issue":"6","key":"33359_CR10","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.4049\/jimmunol.149.6.2055","volume":"149","author":"RW Finberg","year":"1992","unstructured":"Finberg, R. W., White, W. & Nicholson-Weller, A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J. Immunol. 149(6), 2055\u20132060 (1992).","journal-title":"J. Immunol."},{"key":"33359_CR11","doi-asserted-by":"crossref","unstructured":"Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nature. 4 (2004).","DOI":"10.1038\/nrc1251"},{"key":"33359_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1146\/annurev.immunol.21.120601.141135","volume":"21","author":"D Pardoll","year":"2003","unstructured":"Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807\u2013839 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"33359_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/labinvest.2008.54","volume":"88","author":"P Dumont","year":"2008","unstructured":"Dumont, P. et al. Expression of galectin-3 in the tumor immune response in colon cancer. Lab. Investig. 88, 896\u2013906 (2008).","journal-title":"Lab. Investig"},{"issue":"1","key":"33359_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/eji.201141825","volume":"42","author":"SM Ong","year":"2012","unstructured":"Ong, S. M. et al. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur. J. Immunol. 42(1), 89\u2013100 (2012).","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"33359_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: A key system for immune surveillance and homeostasis. Nat. Immunol. 11(9), 785\u2013797. https:\/\/doi.org\/10.1038\/ni.1923 (2010).","journal-title":"Nat. Immunol."},{"key":"33359_CR16","unstructured":"Biorepository GM. RNA and miRNA Isolation from Human Peripheral Blood."},{"key":"33359_CR17","unstructured":"Biosystems A. High capacity cDNA reverse transcription kits for 200 and 1000 reactions protocol. Published online (2010)."},{"key":"33359_CR18","doi-asserted-by":"publisher","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using Real- time quantitative PCR and the 2-\u2206\u2206 CT method. 408 https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","DOI":"10.1006\/meth.2001.1262"},{"issue":"11","key":"33359_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/1541-7786.mcr-10-0225","volume":"8","author":"MJ Rutkowski","year":"2010","unstructured":"Rutkowski, M. J., Sughrue, M. E., Kane, A. J., Mills, S. A. & Parsa, A. T. Cancer and the complement cascade. Mol. Cancer Res. 8(11), 1453\u20131465. https:\/\/doi.org\/10.1158\/1541-7786.mcr-10-0225 (2010).","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"33359_CR20","first-page":"1039","volume":"140","author":"F Niculescu","year":"1992","unstructured":"Niculescu, F., Rus, H. G., Retegan, M. & Vlaicu, R. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 140(5), 1039\u20131043 (1992).","journal-title":"Am. J. Pathol."},{"issue":"11","key":"33359_CR21","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1002\/1097-0142(19940601)73:11<2808::AID-CNCR2820731125>3.0.CO;2-P","volume":"73","author":"M Yamakawa","year":"1994","unstructured":"Yamakawa, M., Yamada, K., Ohrui, H., Ogata, T. & Dobashi, M. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 73(11), 2808\u20132817 (1994).","journal-title":"Cancer"},{"issue":"18","key":"33359_CR22","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/jnci\/djt205","volume":"105","author":"D Ajona","year":"2013","unstructured":"Ajona, D. et al. Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl. Cancer Inst. 105(18), 1385\u20131393. https:\/\/doi.org\/10.1093\/jnci\/djt205 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"33359_CR23","doi-asserted-by":"crossref","unstructured":"Matsutani, M., Suzuki, T. & Hori, T. Cellular immunity and complement levels in hosts with brain tumours. 71(1), 29\u201335 (1984).","DOI":"10.1007\/BF01743288"},{"key":"33359_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000225191","volume":"34","author":"P Maness","year":"1977","unstructured":"Maness, P. & Orengo, A. Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology 34, 87\u201389 (1977).","journal-title":"Oncology"},{"issue":"9","key":"33359_CR25","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20061022","volume":"203","author":"G Girardi","year":"2006","unstructured":"Girardi, G., Yarilin, D., Thurman, J. M., Holers, V. M. & Salmon, J. E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203(9), 2165\u20132175. https:\/\/doi.org\/10.1084\/jem.20061022 (2006).","journal-title":"J. Exp. Med."},{"key":"33359_CR26","doi-asserted-by":"crossref","unstructured":"Yan, J., Allendorf, D. & Yan, R. Advances in experimental medicine and biology. The role of membrane complement regulatory proteins in cancer immunotherapy. 632 (2008).","DOI":"10.1007\/978-0-387-78952-1_12"},{"issue":"3","key":"33359_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/2162402X.2014.979688","volume":"4","author":"S Mamidi","year":"2015","unstructured":"Mamidi, S. et al. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology 4(3), 1\u201312 (2015).","journal-title":"Oncoimmunology"},{"key":"33359_CR28","doi-asserted-by":"publisher","unstructured":"Kelkar, N., Goldberg, B., Dufloo, G. & Ackerman, M. Sex- and species-associated differences in complement-mediated immunity in humans and rhesus macaques. MBio 15(3). https:\/\/doi.org\/10.1128\/mbio.00282-24 (2024).","DOI":"10.1128\/mbio.00282-24"},{"issue":"5","key":"33359_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4161\/mabs.29670","volume":"6","author":"S Meyer","year":"2014","unstructured":"Meyer, S., Leusen, J. H. W. & Boross, P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs 6(5), 1133\u20131144 (2014).","journal-title":"MAbs"},{"issue":"3","key":"33359_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/labinvest.3780038","volume":"8","author":"V Blok","year":"2000","unstructured":"Blok, V., Daha, M. & Tijsma, O. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab. Investig. 8(3), 335\u2013344 (2000).","journal-title":"Lab. Investig"},{"key":"33359_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3109\/10428199409073780","volume":"12","author":"T Seya","year":"1994","unstructured":"Seya, T. et al. Distribution of C3-Step regulatory proteins of the complement system, CD35 (CRl), CD46 (MCP), and CD55 (DAF), in hematological malignancies. Leuk. Lymphoma. 12, 395\u2013400 (1994).","journal-title":"Leuk. Lymphoma"},{"key":"33359_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2141.1992.tb06431.x","volume":"82","author":"H Tomoko","year":"1992","unstructured":"Tomoko, H., Ayako, K., Hiroko, F., Toru, M. & Fukumori, Y. Levels of complement regulatory proteins, CD35 (CRl), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br. J. Haematol. 82, 368\u2013373 (1992).","journal-title":"Br. J. Haematol."},{"key":"33359_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1034\/j.1600-0609.2000.80097.x","volume":"64","author":"D Guc","year":"2000","unstructured":"Guc, D., Canp\u00f5nar, H., Kucukaksu, C. & Kansu, E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur. J. Haematol. 64, 3\u20139 (2000).","journal-title":"Eur. J. Haematol."},{"key":"33359_CR34","doi-asserted-by":"publisher","unstructured":"Fishelson, Z., Donin, N., Zell, S., Schultz, S. & Kirschfink, M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40, 109\u2013123. https:\/\/doi.org\/10.1016\/S0161-5890(03)00112-3  (2003)","DOI":"10.1016\/S0161-5890(03)00112-3"},{"issue":"3","key":"33359_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1615\/CritRevImmunol.v20.i3.20","volume":"20","author":"GD Ross","year":"2000","unstructured":"Ross, G. D. Regulation of the adhesion versus cytotoxic functions of the Mac-1\/CR3\/alphaMbeta2-integrin glycoprotein. Crit. Rev. Immunol. 20(3), 197\u2013222 (2000).","journal-title":"Crit. Rev. Immunol."},{"issue":"3","key":"33359_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.it.2004.01.008","volume":"25","author":"KA Gelderman","year":"2004","unstructured":"Gelderman, K. A., Tomlinson, S., Ross, G. D. & Gorter, A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25(3), 158\u2013164. https:\/\/doi.org\/10.1016\/j.it.2004.01.008 (2004).","journal-title":"Trends Immunol."},{"key":"33359_CR37","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhang, H. & Wen, H. Y. The complement receptors C3aR and C5aR are a new class of immune checkpoint receptor in cancer immunotherapy. Front. Immunol. 10, 1\u20137 (2019).","DOI":"10.3389\/fimmu.2019.01574"},{"key":"33359_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-1-4614-5915-6_11","volume":"772","author":"R Pio","year":"2014","unstructured":"Pio, R., Corrales, L. & Lambris, J. D. The role of complement in tumor growth. Adv. Exp. Med. Biol. 772, 229\u2013262 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"33359_CR39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccell.2018.09.003","volume":"34","author":"TR Medler","year":"2018","unstructured":"Medler, T. R. et al. Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy. Cancer Cell. 34(4), 561\u2013578 (2018).","journal-title":"Cancer Cell."},{"issue":"5","key":"33359_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","volume":"34","author":"A Naing","year":"2018","unstructured":"Naing, A., Infante, J. R., Papadopoulos, K. P., Leveque, J. & Tannir, N. M. PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8\u2009+\u2009T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell. 34(5), 775\u2013791 (2018).","journal-title":"Cancer Cell."},{"key":"33359_CR41","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1158\/2159-8290.CD-16-0698","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W., Mckenzie, J. A. & Hwu, P. Complementing T-cell function: an inhibitory role of the complement system in T-cell \u2013 mediated antitumor immunity. Cancer Discov. 6, 953\u2013956 (2016).","journal-title":"Cancer Discov"},{"issue":"9","key":"33359_CR42","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/ni.1917","volume":"11","author":"J Cardone","year":"2014","unstructured":"Cardone, J., Le Friec, G., Vantourout, P. & Roberts, A. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 11(9), 862\u2013871 (2014).","journal-title":"Nat. Immunol."},{"issue":"8","key":"33359_CR43","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2174\/156800910793357952","volume":"10","author":"N Geis","year":"2010","unstructured":"Geis, N. et al. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by SiRNA sensitizes tumor cells to complement attack in vitro. Curr. Cancer Drug Targets. 10(8), 922\u2013931 (2010).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"33359_CR44","doi-asserted-by":"publisher","first-page":"491","DOI":"10.4049\/jimmunol.174.1.491","volume":"174","author":"PS Bora","year":"2005","unstructured":"Bora, P. S. et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J. Immunol. 174(1), 491\u2013497. https:\/\/doi.org\/10.4049\/jimmunol.174.1.491 (2005).","journal-title":"J. Immunol."},{"key":"33359_CR45","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/B978-0-12-374279-7.17002-X","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 406\u2013415. https:\/\/doi.org\/10.1016\/B978-0-12-374279-7.17002-X (2002).","journal-title":"Nature"},{"key":"33359_CR46","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","volume":"19","author":"LT Roumenina","year":"2019","unstructured":"Roumenina, L. T., Daugan, M., Petitprez, F., Fridman, C. S. & Fridman, W. H. Context- dependent roles of complement in cancer. Nat. Rev. Cancer. 19, 698\u2013715 (2019).","journal-title":"Nat. Rev. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33359-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33359-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33359-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:03:05Z","timestamp":1768345385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33359-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33359"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33359-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles outlined in the Declaration of Helsinki. It was approved by the Human Ethics Review Committee of the Faculty of Medicine, Cairo University and participants were informed in detail about the study and gave their written consents. Participation in the study was voluntary and informed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1630"}}